Bosh sahifaBIIB • BCBA
add
Biogen Inc Cedear
Yopilish kursi
21 300,00 $
Kunlik diapazon
20 670,00 $ - 20 980,00 $
Yillik diapazon
9 930,00 $ - 23 150,00 $
Bozor kapitalizatsiyasi
27,14 mlrd USD
Oʻrtacha hajm
2,47 ming
Narx/foyda
-
Dividend daromadliligi
-
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 2,28 mlrd | -7,14% |
Joriy xarajat | 1,39 mlrd | -1,09% |
Sof foyda | -48,90 mln | -118,34% |
Sof foyda marjasi | -2,15 | -119,80% |
Har bir ulushga tushum | 1,99 | -42,15% |
EBITDA | 647,90 mln | -6,98% |
Amaldagi soliq stavkasi | 12,68% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 3,82 mlrd | 60,66% |
Jami aktivlari | 29,44 mlrd | 4,96% |
Jami passivlari | 11,18 mlrd | -1,33% |
Umumiy kapital | 18,26 mlrd | — |
Tarqatilgan aksiyalar | 146,76 mln | — |
Narxi/balansdagi bahosi | 171,26 | — |
Aktivlardan daromad | 3,82% | — |
Kapitaldan daromad | 4,50% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -48,90 mln | -118,34% |
Operatsiyalardan naqd pul | 511,90 mln | -32,72% |
Sarmoyadan naqd pul | -1,23 mlrd | -6 522,04% |
Moliyadan naqd pul | -137,00 mln | -1 834,18% |
Naqd pulning sof oʻzgarishi | -854,30 mln | -226,41% |
Boʻsh pul | 234,32 mln | -56,76% |
Haqida
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
Tashkil etilgan
1978
Sayt
Xodimlar soni
7 500
